Physician profile
Steven Schepens
NPI 1982719779
$11,971.10
in general payments reported to CMS, 2019-2025
41 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $1,520 · 2021: $2,170 · 2022: $1,981 · 2023: $2,269 · 2024: $1,319 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,752 · Education: $70.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,751.76 |
| Education | $70.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,332.85 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,032.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,021.53 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $924.58 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $908.55 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $770.16 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $748.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $683.94 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Ucb, INC. | $542.46 | 2022-2025 | Nayzilam, Briviact, Fintepla |
| Amgen INC. | $439.39 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.85 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $343.93 | 2019-2024 | Spravato |
| Allergan, INC. | $325.75 | 2019-2020 | |
| Astellas Pharma US INC | $300.87 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $239.70 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schepens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.